Current pharmaceutical design of antituberculosis drugs: future perspectives.
The increasing resistance of Mycobacterium tuberculosis to the existing drugs has alarmed the worldwide scientific community. In an attempt to overcome this problem computer-aided drug design has provide an extraordinary support to the different strategies in drug discovery. There are around 250 biological receptors like enzymes that can be used in principle, for the design of antituberculosis compounds that act by a specific mechanism of action. Also, there more than 5000 compound available in the literature, and that constitute important information in order to search new molecular patterns for the design of new antituberculosis agents. The purpose of this paper is to explored the current state of drug discovery of antituberculosis agents and how the different strategies supported by computer-aided drug design methods has influenced in a determinant way in the design of new molecular entities that can result the future antituberculosis drugs.
Speck-Planche
Alejandro
A
Department of Chemistry, University of Oriente, Santiago de Cuba, Cuba. alejspivanovich@yahoo.es
Scotti
Marcus Tulius
MT
de Paulo-Emerenciano
Vicente
V
D000995:Antitubercular Agents / Q000737:chemistry* / Q000494:pharmacology*; D017076:Computer-Aided Design / Q000639:trends; D004304:Dosage Forms; D015195:Drug Design; D005544:Forecasting; D006801:Humans; D008024:Ligands; D008968:Molecular Conformation; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D021281:Quantitative Structure-Activity Relationship; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy*
D000995:Antitubercular Agents; D004304:Dosage Forms; D008024:Ligands